PGF2, were not significantly related to the menopausal status of the patients or the presence of oestrogen and progesterone receptors.
Human mammary cancers appear to produce prostaglandin-like material, and this may be involved in tumour growth and metastases (Bennet et al., 1977; Rolland et al., 1980) . Most investigations have, however, employed bioassay or radioimmunoassay techniques which do not definitively identify prostaglandins. A single study has reported on determinations performed by GLCmass spectrometry but the number of tumours examined was relatively small (Stamford, 1983) . The present investigation represents a study of 100 human mammary cancers in which PGE2 and PGF2. have been identified and quantitated by GLC-mass spectrometry. Values of prostaglandins have then been related to tumour steroid receptor status.
Materials and methods

Tumours
Tumour was obtained from 100 women with carcinoma of the breast. These patients comprised 15 premenopausal, 10 perimenopausal (within 5 years of the last menstrual period) and 75 post menopausal women. Tumour was removed at mastectomy or biopsy from the primary cancer (in 88 women), by biopsy of invaded lymph node (in 9 cases) or secondary recurrences (in 3 cases). For comparative purposes, material was also obtained from benign fibroadenoma of the breast in 5 women and from histologically normal breast tissue in 3 women. This material was placed on ice and immediately transferred to the laboratory. Following removal of tissue for histopathological diagnosis, the remaining material was dissected free of extraneous fat and divided for prostaglandin and steroid receptor assays.
Measurement ofprostaglandins
Formation of derivatives Tumour samples were weighed and homogenized in ethanol (2.5 ml). To 1 ml duplicates of each sample were added 20 ng of the internal standards, . Oximes were formed by adding hydroxylaminehydrochloride solution (50mg ml -1) in sodium acetate buffer (3 mol P1, pH 5.2) and heating for 30 min at 60°C. The samples were extracted and purified using a C18 Seppak column, washed with 10ml iso-octane and then 10ml 50% methanol to remove neutral lipids. The prostaglandins were then eluted with 90% methanol (10ml). This fraction was evaporated to dryness and the residue dissolved in ethyl acetate:ethanol (1:lv/v), transferred to a small flat-bottomed tube and methylated with 100p1 diazomethane solution. Excess diazomethane and solvent were then evaporated. The residue was further derivatized to the t-butyldimethylsilyl ether by adding 65pl 2M-butyldimethylchlorosilane and 65pl 4M-imidazole (both in dimethylformamide). After mixing, this solution was transferred to a narrow glass tube which was then sealed and heated for 30 min at 130°C. The excess reagents were removed from this mixture by eluting the derivative with 3 ml hexane:ethylacetate (3:1v/v) from a Sephadex LH-20 column. The solvent was evaporated and 20.u1 toluene added to the derivative. About one twentieth of this mixture was injected into the gas chromatograph. detected in all carcinomas. Levels in individual tumours are shown in Figure 1 . Range of values for PGE2 was from 7 to 762 ng g-1 tissue with a median value of 100. The corresponding range for PGF2. in the same samples was from 3 to 475ngg-1 tissue (median 60). Values in a group of 5 fibroadenomas ranged from 2-19ngg-1 tissue (median 9) for PGE2 and 6-14ngg-1 tissue (median 12) for PGF2. and those for 3 specimens of histologically normal breast were 7-14 ng gtissue for PGE2 and 5-18ngg-1 for PGF2a.
Within the group of breast cancers, there was a highly significant correlation between amounts of PGE2 and PGF2. (Figure 2 ). (Spearman's Rank correlation coefficient = 0.543 P<0.001).
There was no significant difference between prostaglandin levels in primary tumours, lymph nodes and secondary recurrences (Data not shown). Nor were there significant differences in amounts of either PGE2 or PGF2. in pre, peri and postmenopausal patients (Figure 3) .
Oestrogen receptor activity was detected in 68 tumours (68%) and the relationship between the presence of receptors and prostaglandin content is shown in Figure 4 . (Figure 5 ). (P <0.8 and P <0.9 respectively by Wilcoxon Rank Sum Test).
Discussion
To date, the evidence that human breast cancers contain significant amounts of prostaglandins has been based on data from either bioassay or radioimmunoassay. These techniques, although of value, do not accurately identify different prostaglandins. In the present study, therefore, we have used the more definitive technique of GLCmass spectrometry which has previously only been employed for prostaglandin measurements in a small group of breast cancers (Stamford, 1983) . It is almost impossible to measure "in situ" levels of prostaglandins within tissue preparations because prostaglandins are not stored in cells but are synthesised rapidly in response to stimuli. Biopsy, processing and homogenization of tumour specimens represent stimuli which would result in production of large amounts of prostaglandins. Determination of prostaglandins in tumours can, therefore, only be directed towards assessing the potential for prostaglandin production rather than measurement of endogenous levels (Green, 1979) . Two types of technique have been adopted in this respect. Tumour may be homogenized directly in ethanol to obtain "basal" levels or incubated with or without added precursor to determine "synthesised" levels. It is not clear which technique more accurately reflects tumour potential for producing a local environment of prostaglandins or indeed if either reflects "in situ" activity. "Basal" levels will include both the normal content of tumour cells and material synthesized between biopsy and inactivation of synthetic ensymes during homogenisation (Bennet, 1982) . The level of prostaglandin 'synthesized" will depend critically on precautions taken to protect the highly labile prostaglandin synthetase system and addition of arachidonate substrate may not mimic tissue levels of precursor. We have, therefore, chosen to measure basal levels of prostaglandins in the present study because this represents the least complicated and most practical method of studying prostaglandins in a large number of cancers.
Using these techniques, measurable amounts of PGE2 and PGF2. were detected in all tumours.
Prostaglandins were identified on the basis of their molecular ions (at m/z 666 PGE2, m/z 653 for PGF2a), retention times and characteristic peaks.
Amounts of PGE2 varied from 7 to 762 ng g-1 tissue and those of PGF2. from 3 to 475 ngg-1 tissue. These amounts are comparable to concentrations demonstrated by other methods (Bennet, 1982) and were higher than those found in benign and normal breast. A strong positive correlation was detected between levels of the two prostaglandins in individual breast cancers as has been previously observed (Fulton et al., 1982) . Although the variation in the amounts of both prostaglandins was large, we have been unable to identify factors accounting for this variation. Levels of tumour prostaglandins appeared to be uninfluenced by menopausal status of the patient, site of tumour biopsy or whether cytosolic steroid receptors were present. The finding of no significant difference in tumour prostaglandin levels between pre, peri and postmenopausal patients agrees with the results of Rolland et al. (1980) who measured "synthesized" levels of prostaglandins in microsomal preparations. Fulton et al. (1982) failed to show an association with PGF2. but reported significantly raised PGE2 levels in postmenopausal women. It has been suggested that oestrogen receptor positive tumours synthesize greater amounts of prostaglandins (Campbell et al., 1982) . Others have been unable to show such a correlation (Rolland et al., 1980; Bennet, 1982) . However, in the study which reported a significant correlation, it was necessary to make a correction for tumour cellularity before the association became apparent. In the present study, a significant correlation was apparent between tumour cellularity and PGE2 but not PGF2a (Figure 6 ). However, multiple regression analysis of PGE2 and PGF2. on both oestrogen receptor and cellularity showed that oestrogen receptor had no significant effect on prostaglandins for given levels of cellularity (for PGE2 t=0.36, for PGF2, t=1.12). Indeed, correcting the results for tumour cellularity may be misleading because this would be based on the assumption that tumour cells within the biopsy were solely responsible whereas other cell types such as macrophages, lymphocyctes, plasma cells and fibroblasts may also be producing prostaglandins. We have, therefore, preferred to express our results in terms of prostaglandins extracted per weight of tumour tissue. Variation in prostaglandins extractable from breast cancers may be due to non-specific, nontumour factors such as the time interval between the biopsy and extraction, and the degree of trauma produced in obtaining the tumour samples. Enzymes associated with prostaglandin synthesis are particularly labile (Egan et al., 1978) and it is essential to minimise any delay in tumour processing. Substantial amounts of prostaglandins may be generated in response to trauma (Green, 1979) and variation in degree of tissue trauma might be expected to be associated with differences in prostaglandins levels. In practice, it is difficult to eliminate tissue trauma as even gentle handling may stimulate biosynthesis of prostaglandins. In this series of tumours, clinical and pathological considerations determined the degree of mechanical trauma to which the specimens were subjected. However, no significant differences were detected between prostaglandins extracted from samples obtained at biopsy and those from mastectomy specimens.
It has been suggested that tumour prostaglandins are associated with prognosis and pattern of metastatic spread of breast cancer. At the present time, data from this study cannot be assessed for these parameters. Most tumours were obtained from patients with early breast cancer who have, as yet, only short follow-up. The absence of positive correlations with other factors of known prognostic value such as steroid receptors and lymph node status could mean that prostaglandins are either of independent significance or unrelated to prognosis. Valid assessment of the data will only be possible when further follow-up of the patients is available.
